On August 5, Revolution Medicines, Inc. rose 5.23% in regular trading, trading near $191.85/share, with turnover of approximately $105 million.

On the news front, multiple catalysts converged to drive the stock higher. The FDA previously formally accepted the company's New Drug Application (NDA) for its core pipeline drug Daraxonrasib for the treatment of previously treated metastatic pancreatic cancer, marking a key regulatory milestone. Concurrently, the European Medicines Agency initiated a phased review to accelerate evaluation of the same drug. Wedbush raised its price target to $192.10 from $181, maintaining an Outperform rating, while the analyst consensus target stands at $203.85.

Additionally, the company is scheduled to report quarterly earnings after market close, with consensus expecting an EPS loss of $-1.93. Market expectations for the commercial prospects of its RAS-targeted therapies continue to build, particularly after Phase 3 data showed Daraxonrasib doubled median overall survival to 13.2 months versus 6.7 months for chemotherapy in metastatic pancreatic cancer patients.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)